Nanosonics Limited (ASX:NAN) is pleased to announce that it has commenced
production and commercial sale of its breakthrough Trophon(TM) EPR ultrasound
probe disinfector system, through distribution partners in New Zealand and Australia.
Shipments, comprising Trophon EPR systems and NanoNebulant(TM) consumables,
have been allocated to fulfil purchase orders already placed on the distribution
partners by their customers, clinical end-users of the products.
The Company has undertaken a full sales launch to ultrasound professionals,
including trade advertising and sales presentations to key opinion leaders and
clinics throughout Australasia. Sales demand is being driven by the unique value
proposition provided by the Trophon EPR system in the medical ultrasound market.
A contributing factor to this demand is the greater awareness and vigilance
of mandated legislation, regulatory requirements and the significant OH&S
issues facing hospital and clinic staff.
The Trophon EPR is now being included in tenders submitted by the Original
Equipment Manufacturers (OEMs). Further, the Company has been advised that the
Trophon EPR has been incorporated as a condition in several new Government tenders,
both in Australia and internationally.
Nanosonics has commenced a broad range of pre-launch activities in Europe,
with first shipments expected in the next quarter of 2009. The Company has established
a strong dealer network throughout Europe, each of whom has committed to commercial
purchases of the Trophon EPR system to support the European launch.
It is expected that the Trophon EPR system will be launched in the near term
into certain key markets in Asia, where the regulatory requirements for sale
have already been met.
Sales demand in this region is being influenced by the recent Guidelines issued
by the US Centre for Disease Control (CDC), Nanosonics now has substantial technical
resources available to pursue additional commercial products based upon its
novel NanoNebulant platform. Prototyping is now well advanced for several new
devices which address substantial global market needs.
The Company is in commercial discussions with both equipment manufacturers
and other potential strategic partners, with a view to bringing devices to market
where the Company's technology can deliver automated, safe, effective and environmentally
sound solutions to the growing range of markets in healthcare and beyond.